
Sysmex Corporation
Sysmex
Sysmex Corporation is a Japanese medical diagnostics company and the global leader in clinical hematology analyzers, holding more than 50% of the worldwide blood cell analysis market. Founded in 1968 and headquartered in Kobe, Japan, Sysmex generated JPY 500.0 billion in FY2025/26 net sales with overseas sales of JPY 441.4 billion (88.3% of the total), and employs 10,861 people across 67 overseas subsidiaries serving 190+ countries. The company's flagship XN-series hematology analyzers, combined with closed-system reagent consumables, create one of the most profitable recurring-revenue models in diagnostics. In September 2025, Sysmex acquired JEOL's clinical chemistry business to extend its product portfolio beyond hematology into chemistry testing.
Strengths: Sysmex commands an effective oligopoly in hematology with over 50% global share, protected by proprietary flow cytometry technology and a closed reagent ecosystem. The company's XN-series analyzers deliver unmatched throughput and precision, with digital morphology (DI-60) and automated slide review systems extending workflow automation. Sysmex earned JPY 87.6 billion in operating profit in FY2024/25, but FY2025/26 operating profit fell 40.8% to JPY 51.8 billion as Chinese demand weakened. The acquisition of JEOL's clinical chemistry business (completed September 2025) broadens the menu into high-growth chemistry segments. International sales consistently exceed 86% of total revenue, providing geographic diversification.
Weaknesses: Sysmex's heavy concentration in a single diagnostic discipline — hematology — exposes the company to category-specific demand cycles and intensifying competition from Abbott's Alinity h-series and Beckman Coulter's DxH platforms. The company's FY2025/26 net sales slipped 1.7% to JPY 500.0 billion and net profit dropped 33.9% to JPY 35.5 billion, reflecting soft demand in China and emerging markets. Sysmex faces pricing pressure in Chinese tender markets as central procurement reforms squeeze instrument attachment rates.Read MoreShow Less
Strengths: Sysmex commands an effective oligopoly in hematology with over 50% global share, protected by proprietary flow cytometry technology and a closed reagent ecosystem. The company's XN-series analyzers deliver unmatched throughput and precision, with digital morphology (DI-60) and automated slide review systems extending workflow automation. Sysmex earned JPY 87.6 billion in operating profit in FY2024/25, but FY2025/26 operating profit fell 40.8% to JPY 51.8 billion as Chinese demand weakened. The acquisition of JEOL's clinical chemistry business (completed September 2025) broadens the menu into high-growth chemistry segments. International sales consistently exceed 86% of total revenue, providing geographic diversification.
Weaknesses: Sysmex's heavy concentration in a single diagnostic discipline — hematology — exposes the company to category-specific demand cycles and intensifying competition from Abbott's Alinity h-series and Beckman Coulter's DxH platforms. The company's FY2025/26 net sales slipped 1.7% to JPY 500.0 billion and net profit dropped 33.9% to JPY 35.5 billion, reflecting soft demand in China and emerging markets. Sysmex faces pricing pressure in Chinese tender markets as central procurement reforms squeeze instrument attachment rates.
Listed market data
6869 · TSE · weeklyHistory →- Market cap
- $8.2 B
- Share price
- JPY 2159.50
- 1Y change
- +12.6%
- Recent change
- +2.1%
- Since first close
- ×19.2
- Revenue (TTM)
- $3.1 B
11-18 → 11-19
from 2001
Financial history
Full market history- 2026-11JPY 2159.50$8.2 B+16.5%
- 2026-10JPY 1853.00$7 B0.0%
- 2026-09JPY 1853.00$7 B+0.4%
- 2026-08JPY 1845.00$7 B-6.0%
- 2026-07JPY 1963.00$7.4 B+22.8%
- 2026-06JPY 1599.00$6.1 B+8.7%
- 2026-05JPY 1470.50$5.6 B+5.3%
- 2026-04JPY 1397.00$5.3 B+1.4%
- 2026-03JPY 1378.00$5.2 B+0.7%
- 2026-02JPY 1368.50$5.2 B-7.0%
- 2026-01JPY 1472.00$5.6 B+0.3%
- 2025-12JPY 1467.00$5.6 B—
Ownership & Control
Shareholding as of 2025-06-30- Controlling entity
- Publicly held — no controlling shareholder disclosed
- Company type
- Brand & Manufacturer
- Insiders
- 27.34%
- Institutions
- 28.65%(224 holders)
- Free float
- 39.43%
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →5 latest headlines1- Sysmex (TSE:6869) Stock May Be A Bargain On Cash Flowfinance.yahoo.com2026-10-10
- Sysmex (TSE:6869) Stock May Be A Bargain On Cash Flow - Yahoo Financefinance.yahoo.com2026-10-10
- Sysmex (TSE:6869) Rebound Puts Fair Value Back In Focus - Simply Wall Streetsimplywall.st2026-10-08
- Transforming Healthcare Through Blood Testing: President Matsui Shares Sysmex’s Vision - シスメックス - Sysmexwww.sysmex.co.jp2026-09-28
- Point of Care Diagnostics Market Forecasts Growth from $20.63B (2026) to $31.46B by 2031, Profiling QuidelOrtho, Sysmex, HemoCue, Trinity Biotech & 15 Other Key Playersfinance.yahoo.com2026-09-16
• XN-series automated hematology analyzers
• Reticulocyte and body fluid analysis
• Digital morphology systems DI-60
Hemostasis & Coagulation – Core Business
• CS-series coagulation analyzers
• Thromboelastography and platelet function testing
Urinalysis – Core Business
• UF-series urine particle analyzers
• UC-series chemistry and sediment review automation
Clinical Chemistry – Core Business
• Chemistry analyzers JEOL acquisition, completed 2025
Flow Cytometry & Lab Automation – Core Business
• Clinical flow cytometers for immunophenotyping
• Sample transport and laboratory information systems
Quick Facts
Headquarters
Founded
Employees
Revenue
Market cap
Factories
Presence
Listing
TSE: 6869Categories
17 categories · scroll for more
Related
Similar listed companies
- Eli Lilly and Company· $1.3 T
- Johnson & Johnson (J&J)· $653 B
- ASML Holding N.V.· $598 B
- Allergan Aesthetics· $508 B
- AbbVie Inc.· $504 B
- General Electric Company (GE)· $405 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website TSE: 6869 , Sysmex FY2025 Business Results (Official IR)
Sysmex Business Overview (Official)
Sysmex JEOL Clinical Chemistry Acquisition Announcement
Sysmex Q4 FY2025 Earnings Call Transcript
